ReviewVaccine2014
Towards a safe and effective chlamydial vaccine: lessons from the eye.
Review in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Pathogenicity and virulence ofVirulence · 2025Review
- Viral Vector-BasedVaccines · 2024Article
- Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.Vaccines · 2024Review
- Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.Pathogens and disease · 2024Article
- Review
- Elimination of Chlamydia muridarum from the female reproductive tract is IL-12p40 dependent, but independent of Th1 and Th2 cells.PLoS pathogens · 2024Article
- A systems serology approach to the investigation of infection-induced antibody responses and protection in trachoma.Frontiers in immunology · 2023Article
- Role of TRAIL-R in Primary and Secondary Genital and Respiratory Chlamydia muridarum Infections in Mice.Microbiology spectrum · 2022Article
- Th1 cells are dispensable for primary clearance of Chlamydia from the female reproductive tract of mice.PLoS pathogens · 2022Article
- A Novel Flow Cytometric Approach for the Quantification and Quality Control ofPathogens (Basel, Switzerland) · 2021Article
- Inhibitory Activity of Pyrroloisoxazolidine Derivatives againstBioMed research international · 2021Article
- Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with theNPJ vaccines · 2020Article
- Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following aNPJ vaccines · 2020Article
- Review
- Diversity in the T cell response to Chlamydia-sum are better than one.Immunology letters · 2018Review
- Pyocyanin Inhibits Chlamydia Infection by Disabling Infectivity of the Elementary Body and Disrupting Intracellular Growth.Antimicrobial agents and chemotherapy · 2018Article
- Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.Expert review of vaccines · 2018Review
- Antichlamydial Dimeric Indole Derivatives from Marine Actinomycete Rubrobacter radiotolerans.Planta medica · 2017Article
- Measuring Trachomatous Inflammation-Intense (TI) When Prevalence Is Low Provides Data on Infection With Chlamydia trachomatis.Investigative ophthalmology & visual science · 2017Article
- The effect of infectious dose on humoral and cellular immune responses in Chlamydophila caviae primary ocular infection.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
As well as being the most common bacterial sexually transmitted infection, Chlamydia trachomatis (Ct) is the leading infectious cause of blindness. The pathogenesis of ocular chlamydial infection (trachoma) is similar to that of genital infection. In the 1960s the efficacy of Ct vaccines against ocular infection was evaluated in major field trials in Saudi Arabia, Taiwan, The Gambia, India and Ethiopia. These trials showed that it was possible to induce short term immunity to ocular infection, and to reduce the incidence of inflammatory trachoma, by parenteral immunisation with killed or live whole organism vaccines. In one study, it was also shown that the incidence of scarring sequelae was reduced in vaccinated children. Detailed studies in non-human primates conducted at this time suggested that vaccination could lead to more severe inflammatory disease on subsequent challenge. Since that time there have been many studies on the immunological correlates of protective immunity and immunopathology in ocular Ct infection in humans and non-human primates, and on host genetic polymorphisms associated with protection from adverse sequelae. These have provided important information to guide the development and evaluation of a human Ct vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.